Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.63 |
| ▸ | NAAA | Q02083 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.58 |
| ▸ | FAAH | O00519 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.48 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327335 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL16582460 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL6281759 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23567381 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL6120008 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL23567378 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL14621023 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL5543839 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL5331194 | 0.98 | CASP2 (0.67) | CASP2NAAAEPHX1FAAHMEN1 | |
| SCHEMBL3310816 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016102562-A1 | FGF21 DERIVATIVES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2016-06-30 | — | — | WO | disclosed |
| CN-102617690-B | Vitamin d derivatives | CHUGAI PHARMACEUTICAL CO LTD | 2015-07-08 | — | — | CN | disclosed |
| US-8927545-B2 | Inhibiting Eph B-3 kinase | DUKE UNIVERSITY (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120238597-A1 | Inhibiting EPH B-3 Kinase | DUKE UNIVERSITY (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238597-A1 | Inhibiting EPH B-3 Kinase | EPHB3, EPHB1, EPHB2 | CASP2 1903/4885NAAA 3141/4885EPHX1 13/4885 |
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | CASP2 3397/4885NAAA 1142/4885EPHX1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.